A digital health intervention for cardiovascular disease management in primary care (CONNECT) randomized controlled trial by Redfern, Julie et al.
Bond University
Research Repository
A digital health intervention for cardiovascular disease management in primary care
(CONNECT) randomized controlled trial
Redfern, Julie; Coorey, Genevieve; Mulley, John; Scaria, Anish; Neubeck, Lis; Hafiz, Nashid;
Pitt, Chris; Weir, Kristie; Forbes, Joanna; Parker, Sharon; Bampi, Fiona; Coenen, Alison;
Enright, Gemma; Wong, Annette; Nguyen, Theresa; Harris, Mark; Zwar, Nick; Chow, Clara K.;








Publisher's PDF, also known as Version of record
Licence:
CC BY
Link to publication in Bond University research repository.
Recommended citation(APA):
Redfern, J., Coorey, G., Mulley, J., Scaria, A., Neubeck, L., Hafiz, N., Pitt, C., Weir, K., Forbes, J., Parker, S.,
Bampi, F., Coenen, A., Enright, G., Wong, A., Nguyen, T., Harris, M., Zwar, N., Chow, C. K., Rodgers, A., ...
Peiris, D. (2020). A digital health intervention for cardiovascular disease management in primary care
(CONNECT) randomized controlled trial. npj Digital Medicine, 3(1), [117]. https://doi.org/10.1038/s41746-020-
00325-z
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
ARTICLE OPEN
A digital health intervention for cardiovascular disease
management in primary care (CONNECT) randomized
controlled trial
Julie Redfern 1,2✉, Genevieve Coorey2,3, John Mulley2, Anish Scaria2, Lis Neubeck4, Nashid Hafiz1, Chris Pitt2, Kristie Weir2,
Joanna Forbes 2, Sharon Parker4, Fiona Bampi5, Alison Coenen2, Gemma Enright1, Annette Wong6, Theresa Nguyen2, Mark Harris7,
Nick Zwar8,9, Clara K. Chow 1,2, Anthony Rodgers2, Emma Heeley 2, Katie Panaretto10, Annie Lau11, Noel Hayman12,
Tim Usherwood1,2,13 and David Peiris 2
Digital health applications (apps) have the potential to improve health behaviors and outcomes. We aimed to examine the
effectiveness of a consumer web-based app linked to primary care electronic health records (EHRs). CONNECT was a multicenter
randomized controlled trial involving patients with or at risk of cardiovascular disease (CVD) recruited from primary care (Clinical
Trial registration ACTRN12613000715774). Intervention participants received an interactive app which was pre-populated and
refreshed with EHR risk factor data, diagnoses and, medications. Interactive risk calculators, motivational messages and lifestyle goal
tracking were also included. Control group received usual health care. Primary outcome was adherence to guideline-recommended
medications (≥80% of days covered for blood pressure (BP) and statin medications). Secondary outcomes included attainment of
risk factor targets and eHealth literacy. In total, 934 patients were recruited; mean age 67.6 (±8.1) years. At 12 months, the
proportion with >80% days covered with recommended medicines was low overall and there was no difference between the
groups (32.8% vs. 29.9%; relative risk [RR] 1.07 [95% CI, 0.88–1.20] p= 0.49). There was borderline improvement in the proportion
meeting BP and LDL targets in intervention vs. control (17.1% vs. 12.1% RR 1.40 [95% CI, 0.97–2.03] p= 0.07). The intervention was
associated with increased attainment of physical activity targets (87.0% intervention vs. 79.7% control, p= 0.02) and e-health
literacy scores (72.6% intervention vs. 64.0% control, p= 0.02). In conclusion, a consumer app integrated with primary health care
EHRs was not effective in increasing medication adherence. Borderline improvements in risk factors and modest behavior changes
were observed.
npj Digital Medicine           (2020) 3:117 ; https://doi.org/10.1038/s41746-020-00325-z
INTRODUCTION
Cardiovascular disease (CVD) is responsible for most of the global
burden of non-communicable diseases (NCD) accounting for over
17 million deaths globally in 20161. Internationally, guidelines
place adherence to prevention medication and, healthy lifestyle
behaviors at the core of CVD risk management, primary and
secondary prevention recommendations2,3. However, use of
evidence-based medications and lifestyle change are typically
suboptimal4 and with an aging population the health burden is
escalating. Thus, implementation of primary and secondary
prevention strategies (such as healthy living, adherence to
medicines) are an international priority requiring development
and testing of innovative and scalable strategies that are
evidence-based and better support patients5.
Major advances in internet and mobile technology over the past
decade provide potential solutions to reduce the burden of CVD
and broaden the reach of health care. Worldwide, more than five
billion people own mobile phones6 and opportunities to deliver
healthcare digitally are expanding exponentially with strategies
such as internet portals, data-driven precision medicine and
smartphone applications (apps)7. Although scientific evidence of
their effectiveness is growing, research lags behind the rapid
emergence and adoption of technology innovations targeting
health-related behaviors. Benefits of interactive internet portals
have been demonstrated in managing chronic conditions8. Our
randomized controlled trial (RCT) found a physician-focused
decision support tool to be effective in increasing CVD risk
assessment when embedded within the primary care clinical
record system9. In particular, personalized risk score information
that is explained on a visually interesting interface, can make the
impact of improving biometric risk factor values (for example,
blood pressure), or behaviors (for example, smoking cessation),
more compelling9. Hypothesized as a useful springboard to more
engagement by patients with CVD risk factor control, the concept
was adapted to a consumer-facing resource in the current trial.
Other trials have demonstrated the benefits of apps for improving
medication adherence10 and text messages for cardiovascular risk
reduction11. However, to the best of our knowledge these
interventions are almost all stand-alone where data is entered
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into the system manually and they are not integrated with the
patient’s electronic health record (EHR).
Despite the potential for access to one’s EHR to increase and
improve consumer engagement with disease prevention actions,
relatively little is known about the effectiveness of such
interventions for risk factor control. Personal EHRs now form a
core component of many national health reform strategies12 but
often stand-alone from consumer-controlled devices or apps. In
the Australian primary care setting, EHRs offer software systems
that assist clinicians with drug prescribing, referrals, coordination
of care, clinical coding, billing, quality improvement activities and,
reporting13. According to a recent American survey, over two-
thirds of adults over 55 years of age own a smartphone and over
85% use the internet with the numbers are increasing annually14.
As such, use of EHRs to auto-populate consumer-focused digital
health interventions has promise, but robust evidence is not
available about effectiveness in reducing CVD risk. Therefore, the
aim of this study was to evaluate the effect of a consumer-focused
digital health intervention, integrated with each participant’s
primary care EHR, on guideline-recommended medication adher-
ence, cardiovascular risk factor control and, lifestyle behaviors at
one year in people at moderate to high risk of CVD.
RESULTS
Overview of cohort
In total, 7457 potentially eligible patients were identified using the
primary care EHR and 3905 were excluded by their GP. We
approached 3552 patients, 2618 did not meet eligibility criteria or
declined participation and 934 were enrolled and randomized
(Fig. 1). At 12-month follow-up 13 participants had withdrawn
from the study and 30 did not consent to data linkage to access
pharmacy dispensing data (Fig. 1). At baseline, the groups were
well matched for demographics, cardiovascular risk factors and
medication prescriptions and the mean age of participants was
67.6 (±8.1) years, 77% were male and 41% had existing CVD (Table
1). One-third of participants had existing coronary heart disease
(33.3%), peripheral arterial disease (3.6%), chronic kidney disease
(3.0%), atrial fibrillation (10.8%), heart failure (1.1%), and a previous
stroke (9.3%).
Results for primary and secondary outcomes
Overall, 93% (451/486) of intervention group participants com-
menced use of the intervention (Fig. 2). Thereafter, participants
were classified as non-adopters (no logins after the training
session—13%, 58/451), low-users (at least one login any across
any 3 months of the follow-up period—47%, 211/451) or high-
users (at least one login in any 4 months of the follow-up period—
40% 182/451). Adherence to guideline recommended medications
did not differ significantly between levels of intervention use (p=
0.44). At 12 months, the intervention group had a non-significant
higher proportion of participants achieving the primary outcome
of ≥80% medication days covered than in the control group
(32.8% vs. 29.9%; RR 1.07 [95% CI 0.88–1.20]) (Fig. 3). The relative
risk was broadly unchanged when adjusted in multivariate
analyses for age, sex, and diabetes status. There were no
significant differences between the control and intervention
groups on the primary outcome for any of our pre-specified
sub-groups of gender, age, baseline eHEALS, and CVD subgroups
(Fig. 4).
At 12 months, there was a borderline improvement in BP and
LDL control rates in intervention vs. control (17.1% vs. 12.1%, RR
1.41 95% CI 0.98–2.03, p= 0.07), however control rates remained
low overall in both study arms. There were no significant
differences between the intervention and control groups in mean
LDL cholesterol (2.5 vs. 2.4 mmol/L, mean difference −0.08 mmol/
L, 95% CI −0.22 to 0.05, p= 0.24) and SBP (136.3 vs. 136.4 mmHg,
mean difference 0.12 mmHg, 95% CI −2.21 to 2.45, p= 0.92). For
lifestyle behaviors, there were significantly more participants
meeting recommended levels for physical activity (87 vs 79.7%,
p= 0.02) in the intervention than the control group (Fig. 3). There
were no significant differences in any of other lifestyle-related
behaviors including quality of life scores and HLQ scores. For
e-health literacy scores there were significant improvements in
participants meeting the pre-defined threshold of high e-health
literacy in the intervention vs. control arm (72.6% vs. 64.0%,
p= 0.016). There were few all-cause hospitalizations (59 vs. 54)
and deaths (2 vs. 1) in both intervention and control groups,
respectively. Owing to small numbers significance testing was not
performed.
DISCUSSION
Among patients with or at high risk of CVD, a consumer-focused
and EHR-integrated software application did not improve
adherence to guideline recommended medicines. The study
population had low to very low medication adherence rates and
concomitant risk factor control rates at baseline and there was
only a marginal improvement post-intervention. The minimal
effects on most outcomes occurred despite reasonable imple-
mentation fidelity. The findings are concerning given this
population is at high to very high risk of experiencing either a
first or subsequent CVD event. The evidence base for guideline-
recommended treatments (BP-lowering medications and statins)
is well established and when these medications are used in
combination they can lower risk of a CVD event by around 40%15.
Optimal medication use (combined BP and statin medication
coverage for at least 80% of the previous 12-month period) was
observed in only around one-third of people with around a half of
people taking BP medications consistently and only 40% taking a
statin over a 12-month period. These gaps are well known and in
the Australian primary care context have changed little over the
last two decades.
The adherence literature related to CVD medications has
repeatedly shown that adherence is heterogeneously impacted
by disease factors, therapy factors, healthcare factors, patient
factors and, social factors16. As such, strategies to improve
adherence tend to have mixed success. The large treatment gaps
identified in our study and the minimal movement with this
intervention suggests more intensive, system wide strategies are
needed to address this intractable problem. Traditionally, inter-
vention approaches look at supply side (provider and system)
strategies and demand side (consumer-focused) strategies. Digital
health interventions for cardiovascular risk are proliferating andFig. 1 Participant flow. GP general practitioner.
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effect sizes vary greatly. On the consumer side, the Text2Pre-
ventCVD Collaboration found text messaging systems have
modest but potentially important reductions in cardiovascular
risk factors17. Similarly, supply-side interventions to improve
quality include audit and feedback, decision support tend to
show mixed outcomes18. Patient and provider education strate-
gies are moderately successful. A recent systematic review of
strategies to increase statin prescribing rates shed some insights
on both sides—patient education initiatives were effective in four
of seven trials and two trials that combines electronic decision
support with audit and feedback were effective19. More recently,
behavioral economics studies are emerging but also inconclusive
to date—one recent study used payments to providers and/or
patients to improve adherence rates to statins and found that only
the combined provider and patient incentives were effective in
lowering LDL cholesterol and that overall the intervention effects
were modest and not cost-effective20.
This mixed evidence base suggests that contextual factors at
multiple levels—health system, service, provider, patient, and
community levels—play a role in influencing the effectiveness of
Table 1. Baseline characteristics.
Interventiona (N= 486) Controla (N= 448) Total (N= 934)
Demographics
Age, mean (SD) years 66.8 (8.4) 68.4 (7.8) 67.6 (8.1)
Male, n (%) 368 (75.7) 348 (77.7) 716 (76.7)
Ethnicity, n (%)
Caucasian 406 (83.5) 396 (88.4) 802 (85.9)
Asian 22 (4.5) 17 (3.8) 39 (4.2)
Aboriginal or Torres Strait Islander 27 (5.6) 10 (3.8) 37 (4.0)
Other 31 (6.4) 25 (5.6) 56 (6.0)
Education <12 years, n (%) 15 (3.1) 13 (2.9) 28 (3.0)
Weekly household income, n (%)
$AU0–799 105 (21.7) 96 (21.4) 201 (21.6)
$AU800–1999 180 (37.1) 155 (34.6) 335 (35.9)
>$AU2000/week 116 (24.0) 119 (26.5) 235 (25.2)
No response 83 (17.1) 78 (17.4) 161 (17.3)
Clinical data+risk factors
High risk of cardiovascular disease, n (%) 285 (58.6) 266 (59.4) 551 (59.0)
Existing cardiovascular disease, n (%) 201 (41.4) 182 (40.6) 383 (41.0)
Diabetes 160 (32.9) 111 (24.8) 271 (29.0)
Mean body mass index (SD) (kg/m2) 29.9 (5.7) 29.7 (5.1) 29.8 (5.4)
Body mass index ≥30 kg/m2, N (%) 205 (42.2) 188 (42.1) 393 (42.1)
Waist circumference, mean (SD) (cm) 105.7 (14.9) 106.4 (13.6) 106.0 (14.3)
Mean systolic blood pressure (SD) (mmHg) 137.3 (15.9) 139.0 (16.6) 138.1 (16.3)
Mean diastolic blood pressure (SD) (mmHg) 78.9 (10.6) 79.8 (10.8) 79.3 (10.7)
LDL-C, mean (SD) (mmol/L) 2.6 (1.04) 2.6 (0.98) 2.6 (1.01)
Meeting target for BPb, n (%) 195 (40.1) 165 (36.8) 360 (38.5)
LDL-C ≤ 2mmol/L, n/N (%) 137/438 (31.3) 121/411 (29.4) 258/849 (30.4)
Meeting BP and LDL targetc n/N (%) 54/438 (12.3) 46/411 (11.2) 100/849 (11.8)
HbA1c, mean (SD) (mmol/mol) 7.0 (1.2) 7.1 (1.3) 7.0 (1.3)
Current smoker, n/N (%) 63/483 (13.0) 57/443 (12.9) 120/926 (13.0)
Physically inactive, n/N (%) 61/419 (14.6) 62/387 (16.0) 123/806 (15.3)
Quality of life and health literacy
eHeals score, mean (SD) 27.0 (6.43) 27.0 (6.41) 27.0 (6.42)
eHEALS score ≥26, n/N (%) 326/483 (67.5) 287/448 (64.1) 613/931 (65.8)
EQ5D score/100, mean (SD) 80.1 (13.8) 79.4 (13.8) 79.8 (13.8)
Self-reported medication use
Lipid lowering, n/N (%) 259/460 (56.3) 212/431 (49.2) 471/891 (52.9)
Antihypertensives, n/N (%) 287/460 (62.4) 275/431 (63.8) 562/891 (63.1)
Antithrombotics, n/N (%) 180/460 (39.1) 183/431 (42.5) 363/891 (40.7)
≥80% medication days covered, n/N (%) 133/460 (28.9) 122/431 (28.3) 255 (28.6)
N number of participants in denominator, n number of participants in the numerator, SD standard deviation, LDL-C low density lipoprotein cholesterol, HbA1c
glycated hemoglobin, EQ5D EuroQual 5D.
aDenominators are included where the denominator differed from the column total.
bBP target defined as: ≤130/80 mmHg for CVD, diabetes or albuminuria or ≤140/90 mmHg for all others.
cLDL-cholesterol target defined as <2.0 mmol/L.
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these strategies. The recently published Non-adoption, Abandon-
ment, Scale-up, Spread and Sustainability (NASS) framework
provides a mechanism for explicitly assessing complexity across
multiple domains to understand adoption barriers and enablers
with technology interventions21. Two NASS domains of particular
importance in this study was the value proposition to users and
the adopter system. The CONNECT intervention has multidimen-
sional components and although it appeared to be viewed
favorably, particularly for goal setting and taking lifestyle actions it
may have had little value to users in relation to medication
management. There was also complexity with the adopter system
which was attempting to promote a more engaged discussion
between provider and patient by integrating the application with
EHR systems. This link was perhaps not sufficiently strong and
research on the impact of direct messaging between patient and
providers is an area for greater exploration. A more detailed
examination of the impact on health-related behavior and how
the EHR-linked strategy was received, used, and accepted by
patients and providers in this study has been reported
elsewhere19.
Importantly, in this study there was some misalignment in
results in terms of medication prescription and risk factor
measurements and qualitative consumer/patient usefulness and
perceived value. This is a common potential problem for RCTs that
have a focus on behavior change based on complex interventions
where there are multiple moving parts22. Together with the
improvements in self-reported physical activity, our findings
suggest there may have been some value to users for lifestyle
changes and motivation. For example, qualitative research
conducted alongside this RCT found that 40% of participants
reported using the web-app improved their mental health and
well-being, 47% reported higher physical activity levels and 61%
reported healthier eating23. In addition, the qualitative research
found 73% of users reported benefiting from personalized CVD
risk score; 69% liked the goal tracking; 52% benefited from the risk
factor self-monitoring and 54% liked the motivational health
tips24. The observed disparity between objective clinical outcomes
and patient preferences is an important consideration when
evaluating this research and future RCTs of complex interventions.
Other studies have also highlighted the importance of relevance
of outcome measures to consumers/patients25. This is an area that
requires further research to help understand how future studies
can ensure emphasis on outcomes that are of high value to
patients but are also scientifically robust so we can most
effectively estimate the potential benefits of digital health
interventions that are consumer-directed.
Fig. 2 Intervention screen shots.
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Study limitations include the following. First, as mentioned in
the “Methods” section, the study was originally powered on risk
factor control and we were aiming to recruit 2000 individuals. This
resulted in a slight imbalance in numbers in the control and
intervention groups although no major difference in measures.
Despite low withdrawal rates, recruitment proved challenging
where primary care practices are not well supported to undertake
research. We had to revise the recruitment target to 1000 patients
and a more appropriate primary outcome (prescription of
evidence-based medications). It is possible that given the trend
to significance in risk factor target control that the study was
underpowered to show an effect, however, even if such an effect
was observed it would have been modest at best and the broad
conclusions remain unchanged. Second, there was a much higher
proportion of men recruited to the study than women. The
reasons for this are complex and are related to both a higher
proportion of men identified at high CVD risk, but also a higher
proportion of men than women agreeing to participate in the
study. This is important given the emerging data on gender
disparities in both health status but also health care. Third, the
study was conducted in mainly urban primary care practices in
one city and practice level factors may be different in other
settings which may lead to different conclusions. Also, two
practices experienced challenges with installing the software to
upload data to the shared EHR and this limited the ability of these
sites to refresh information from the patient record into the
CONNECT application. Finally, due to the low numbers of ACCHSs
recruited, we are not able to make any scientific conclusions about
differential impacts for Aboriginal and Torres Strait Islander people
compared with the general study population and hence have not
attempted to do so. This would need to be the subject of further
specialized research.
In conclusion, a consumer app integrated with primary health
care EHRs was not effective in increasing medication usage in a
population at high risk of CVD events with low pre-existing use of
recommended medications. Borderline improvements in risk
factor control and modest behavioral changes were observed.
When considering the current evidence of behavior change
strategies for CVD risk reduction, this study affirms that such
interventions remain challenging to implement and to achieve
clinical effectiveness. Innovative approaches to intensify the
effects of such interventions are needed and it is likely such
approaches need to target multiple levels of the health system.
METHODS
Study design and participants
The Consumer Navigation of Electronic Cardiovascular Tools (CONNECT)
study was a parallel-design, single-blind randomized clinical trial enrolling
934 patients with, or at high risk of, CVD presenting at 23 Australian
primary care practices and one Aboriginal Community Controlled Health
Service (ACCHS) with an average follow-up of 12 months (Fig. 1). The
protocol is detailed elsewhere26. Participants in both intervention and
control groups received usual health care, but those in the intervention
arm were given access to a web application that was integrated with their
primary health care EHR. Participants provided written informed consent.
Ethical approval was obtained from the University of Sydney Human
Research Ethics Committee (2013/716) and the New South Wales
Aboriginal Health and Medical Research Council (959/13).
Consenting adult patients (>18 years) with access to the internet at least
once a month via mobile phone, tablet or computer, and at moderate to
high risk of a CVD event were eligible to participate. Participants had to
have presented to a participating primary care practice or health service
twice in the last 2 years and once in the last 6 months. Moderate to high
cardiovascular risk was defined as having (i) a 5-year CVD risk ≥10% using
the Framingham risk equation27; (ii) a clinically high risk condition based
Fig. 3 Trial outcomes. CI confidence interval, RR relative risk, BP blood pressure, LDL low-density lipoprotein cholesterol, BMI body mass
index, kg kilogram, m meter.
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on Australian guidelines (Aboriginal/Torres Strait Islander and age >75
years, diabetes and age>60 years, diabetes and albuminuria, eGFR<45ml/
min, systolic blood pressure (BP) ≥ 180mmHg, diastolic BP ≥ 110mmHg,
total cholesterol >7.5 mmol/L) or an established CVD diagnosis (ischemic
heart disease, stroke/transient ischemic attack, peripheral vascular
disease)27. Potential participants with a severe intellectual disability, or
insufficient English to provide written, informed consent were excluded.
Recruitment
Primary health care services in Sydney, New South Wales, Australia were
recruited. Of these, 23 were general practices and one was an ACCHS.
Software to enable integration of the EHR with the consumer portal was
installed at each participating site. A reimbursement of AUD$50 per
participant recruited was made to participating practices to support
administrative time of practice staff. All software license costs and
technical support were provided free of charge to the study sites for the
duration of the trial. Royal Australian College of General Practitioners (GPs)
Quality Improvement and Continuing Professional Development points
were also offered to participating GPs to support their professional
development requirements in terms of contributing to research and
quality improvement.
Recruitment took place between November 2014 and May 2017 (follow-
up until July 2018). Potential participants who met attendance and clinical
eligibility criteria were initially identified by study personnel using a data
extraction tool routinely used in Australian primary health care software
systems. Once identified, the list of potential participants was reviewed by
the attending GP to identify unsuitable patients. All others were then
mailed a study invitation letter from their GP and received a follow-up
telephone call from study personnel. During the phone call, eligibility
including internet access were confirmed. If the person was interested in
participating, an in-person appointment at the practice or health service
was arranged during which written informed consent was obtained prior
to baseline assessment and randomization. Consent was separately
obtained for linkage with federal administrative data from the Australian
Medicare Benefits Scheme (MBS), to determine health service utilization
and, the Pharmaceutical Benefits Scheme (PBS), which contains the
dispensing data required to ascertain proportion of days covered with
guideline recommended medications.
Randomization and masking
Participants were randomized to either have access to the CONNECT web
application in addition to their usual health care (intervention) or receive
their usual health care without access to the web-application (control). In
both groups, any advice and/or other interventions provided by the GP/
health service continued at their discretion. Randomization was conducted
independently using a central computer-based randomization service with
a 1:1 ratio. A permuted block sequence was used with stratification by
practice, baseline CVD risk status and, Aboriginal/Torres Strait Islander
status. The random allocation sequence was concealed from study
personnel, and took place after collection of baseline data. Study personnel
taking baseline and follow-up measurements were blinded to group
allocation and participants were asked not to discuss whether they were
receiving the intervention or not during their follow-up visit.
Intervention
The CONNECT digital health intervention was a consumer-focused,
responsive web application with integration of data from the primary
health care EHR. It was accessible on any internet-enabled device
(smartphone, tablet, laptop, or personal computer) and was developed
using a persuasive and user-centered design process28. Prior to participant
recruitment, software was installed at each participating primary care
service to enable upload of selected personal health data into the patients’
secure portal (Extensia Pty Ltd, Brisbane, Australia). Uploaded data
included medical diagnoses, prescribed medications, physical measure-
ments (weight, waist circumference and, blood pressure), cholesterol
record and hemoglobin A1c (HbA1c) for diabetic patients. The consumer
application has multiple components (Fig. 2) to encourage participants to:
(i) use every-day familiar devices to increase understanding of the
relationship to CVD prevention of lifestyle-related behavior, medication
adherence and, regular discussion of these topics with their GP; and (ii) use
one or more of self-monitoring, goal setting and, digital messaging
functions to facilitate better adherence to these actions. Registered
participants had access to numerous features that facilitated knowledge,
support and, goal-setting in relation to their personal cardiovascular risk
including:
● An auto-populated list of their current medical conditions and
prescribed medications with links to more detailed information to
enhance knowledge.
● A personalized CVD risk score where patients could see the relation-
ship of their risk factors to the score estimation, then use interactive
functionality to visually see the impact of managing their risk factors
on their absolute risk (Fig. 2).
● Interactive tools and resources to assist with care navigation; alongside
data imported from their EHR where patients could log additional
physical measurements taken at home and track their progress with,
for example, blood pressure control or weight reduction if relevant.
Fig. 4 Sub-group analyses for the primary outcome. yrs years, eHEALS eHealth literacy score, CVD cardiovascular disease.
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Calendar links also enabled the patient to record due dates for test
updates, for example cholesterol measurement.
● Interactive goal-setting based on healthier eating, physical activity,
smoking cessation and emotional well-being as well as goal
achievement tracking with virtual rewards to facilitate and motivate
lifestyle changes.
● An interactive social media component with which participants could
read and/or write comments, ask questions or share stories that was
moderated by trained clinical staff.
● Optional receipt of personalized CVD prevention tips and motivational
messages related to diet, medications and lifestyle via email and/or
short message service (SMS) that were developed using a published
process29 and have previously been found to be effective11 and useful
for patients30 in improving cardiovascular risk.
Study personnel supported intervention arm participants over 12 months
using standard protocols to ensure uniformity of support activities and
included health professionals with nursing, dietetics, and pharmacy
training. Participants were trained in use of the application either in
person or by telephone and provided with a printed reference guide if
needed. Thereafter, they were contacted by telephone and/or email at
scheduled intervals: week 2, week 6, week 12, and week 26. During these
routine support calls, staff answered questions, repeated aspects of the
initial training if requested, explained clinical content if needed, and
addressed navigation, function, or other software-related issues. All
communications were logged by time requirement and content, and
software trouble-shooting was referred to a technical help desk.
Participants could contact research staff by telephone or email whenever
they needed additional support. To ensure blinding of outcome
assessments, different personnel supported the intervention participants
to those who conducted the baseline and 12-month assessments.
Data collection procedures
Primary data were collected at face-to-face assessments at baseline and
face-to-face or telephone assessments at end of study (12 months) by
research assistants who were blinded to group allocation. A Standard
Operating Procedure was followed by all research assistants to optimize
uniformity and completeness of data collection and to ensure standardiza-
tion of physical measurements and data entry. Data were entered into a
case report form and a purpose-built, secure online database. The software
installed at each practice or health service to facilitate integration of the
EHR with the consumer portal also enabled relevant clinical data to be
extracted during the study period. In addition, PBS and MBS data were
obtained from the Australian Government Department of Human Services
to assess prescription medications dispensed. Site monitoring visits were
performed periodically to ensure quality documentation, correct software
function, and adherence to various milestones for study personnel contact
in the follow-up period for intervention arm participants.
Outcomes
The primary outcome was the proportion of days covered with guideline
recommended medications at 12 months. This was defined based on the
proportion of maximum medication dispensed from the patient’s
pharmacy using national PBS administrative dispensing data. All medica-
tions of interest for this study are processed via this system regardless of
the pharmacy visited. The primary outcome was defined as met if at end of
study ≥80% of maximum medication had been dispensed in the previous
12 months for at least one BP-lowering medication AND a statin
medication. For people with or at high risk of CVD, Australian guidelines
recommend prescription of at least one BP lowering medication and a
statin unless contraindicated27. People with established CVD are addition-
ally recommended an anti-thrombotic agent (most commonly aspirin)
however, because aspirin is usually available over the counter and is not
reliably captured in the national PBS dataset we did not include it in the
primary outcome.
Secondary and tertiary outcomes at 12 months included:
1. The proportion of participants whose BP AND fasting low-density
lipoprotein (LDL) cholesterol were meeting Australian guideline
targets (defined as: ≤130/80mmHg for CVD, diabetes, or albumi-
nuria or ≤140/90mmHg for all others, AND LDL-cholesterol
<2.0 mmol/L)27.
2. Proportion meeting individual targets for BP and LDL cholesterol.
3. Mean difference in SBP and LDL levels.
4. Proportion of days covered with BP lowering medication and statin
medication separately.
5. Smoking—point abstinence (verified by carbon monoxide meter
where CO > 8 ppm represents recent tobacco smoking)31.
6. Obesity—proportion with a body mass index >30 kg/m2.
7. Self-reported physical activity based on World Health Organization
(WHO) Global Physical Activity Questionnaire32.
8. Health-related Quality of life—EQ5D (version 5L with Australian
standardized weights)33.
9. Fruit and vegetable intake, fish, salt, and saturated fat intake—self-
reported portions consumed in 7 days prior and compared with
published guidelines recommendations34.
10. Health Literacy (Health Literacy Questionnaire, HLQ)24.
11. e-health literacy (eHealth literacy score, eHEALS) with a threshold
score of 26 set as an estimate of high or low eHealth literacy where
higher scores represent better eHealth literacy35.
12. All-cause mortality (medical records); cardiovascular and renal
events, new onset diabetes (self-report verified by the primary care
record) and; hospital admissions (self-report verified by primary care
record).
In our original study protocol the primary outcome was BP and LDL
target attainment (secondary outcome number 1 listed above), however
due to our inability to reach the original recruitment target of 2000
participants, the study steering committee and ethics committee approved
changing this to a secondary outcome and making medication adherence
our primary outcome. This was implemented before end of study data
collection commenced.
Statistical analyses
Using the pre-randomization baseline rates, we assumed the proportion of
people with >80% coverage with guideline-recommended medications
was 28%. A total sample size of 1000 participants, allowing for a 20% loss
to follow-up would have 90% power to detect an absolute improvement of
at least 10% using two-sided tests, with p values of <0.05 judged as
significant. For the original primary outcome of BP and LDL target
attainment, this sample size provided 80% power to detect a 7% absolute
improvement, assuming a baseline control rate of 11%. All statistical
analyses were conducted blinded to group allocation.
A pre-specified statistical analysis plan that was finalized prior to
database lock was followed. The analysis was done by an independent
statistician using SAS (version 9.3). Primary analyses were unadjusted,
following an intention-to-treat principle and conducted blind to
treatment allocation. Multivariate analyses were performed to adjust
for any significant differences between each study arm. Pre-specified
sub-group analyses were conducted to compare outcomes based on
gender, age, baseline, eHEALS, and CVD status (established CVD
compared vs. high CVD risk). Mean risk factor levels were compared
between groups in terms of relative risks (RR), 95% confidence intervals
(CIs), and two-sided p values. Characteristics were compared between
groups using independent t tests for continuous or Χ2 tests for
categorical variables. Mann–Whitney U tests were used where data
were not normally distributed.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The data that support the findings of this study are available from the corresponding
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CODE AVAILABILITY
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